You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The collaboration will focus on the discovery, development, and commercialization of targeted immune evasion therapies for patients with cancer.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.
